Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding historyFinancial support: This work was supported by grants from the CONICET, Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT, MINCyT), Fundación Rene Barón and Academia Nacional de Medicina, Buenos Aires, Argentina.
10 April 2010
Accepted after major revision: 15 July 2010
24 November 2017 (online)
The diagnosis and management of von Willebrand disease (VWD) in paediatrics is challenging. Our aim was to review patient’s characteristics related to biological and clinical response to DDAVP in children with low von Willebrand factor (VWF) levels and bleeding history from a single institution. We included a retrospective cohort of 221 children (median age 11 years; 137 females): 27 type 1 (VWF levels within 15–30 IU dL-1) and 194 possible type 1 (VWF levels within 31–49 IU dL-1). The DDAVP infusion-test was performed in 214/221 children, 93.4% of whom showed good response. Patients with type 1 were at higher risk of DDAVP-test failure: 9/26 (34.6%) vs. 18/188 (9.6%) with possible type 1 (RR 3.44, 1.75–6.79; p= 0.002, Fisher’s exact test). In 68 children, the clinical response to DDAVP was evaluated 87 times: i) to stop bleeding: menorrhagia (13), mucocutaneous (12), haemarthrosis (1); and ii) to prevent surgical bleeding: adenotonsillectomy (17), major (15) and minor surgery (10); and dental procedures (19). No major adverse events or bleeding were observed. The treatment was effective with one single dose of DDAVP in almost all patients, without antifibrinolytic or local therapy, except in a girl with severe haemorrhage during menarche who required replacement therapy. In conclusion, patients with VWD type 1 were at higher risk of no response to DDAVP infusion-test. In this series, one dose of DDAVP proved effective and safe for children with VWD. Since this is a safe, effective and affordable therapy, we consider that a wider use should be promoted, especially in developing countries.
- 1 Bolton Maggs PHB, Lillicrap D, Goudemand J. et al. von Willebrand disease update: diagnostic and treatment dilemmas.. Haemophilia 2008; 14: 56-61.
- 2 Tosetto A, Rodeghiero F, Castaman G. et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).. J Thromb Haemost 2006; 04: 766-773.
- 3 Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis.. Thromb Haemost 2008; 99: 851-862.
- 4 van Vliet HH, Kappers-Klunne MC, Leebeek FWG. et al. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.. Thromb Haemost 2008; 100: 462-468.
- 5 Nichols WL, Hultin MB, James AH. et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA).. Haemophilia 2008; 14: 171-232.
- 6 Millar CM, Riddell AF, Brown SA. et al. Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: influence of glycosylation, proteolysis and gene mutations.. Thromb Haemost 2008; 99: 916-924.
- 7 Cash JD, Gader AMA, de Costa J. The release of plasminogen activator and factor VIII to lysine vasopressin, arginine vasopressin, I-desamino-8-d-arginine vasopressin, angiotensin and oxytocin in man.. Br J Haematol 1974; 27: 363-364.
- 8 Mannucci PM, Aberg M, Nilsson IM. et al. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.. Br J Haematol 1975; 30: 81-93.
- 9 Mannucci PM, Ruggeri ZM, Pareti FI. et al. 1-Deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases.. Lancet 1977; 01: 869-872.
- 10 Sutor AH. DDAVP is not a panacea for children with bleeding disorders.. Br J Haematol 2000; 108: 217-227.
- 11 Nolan B, White B, Smith J. et al. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.. Br J Haematol 2000; 109: 865-869.
- 12 Gill JC, Ottum M, Schwartz B. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.. J Pediatr 2002; 140: 595-599.
- 13 Revel-Vilk S, Schmugge M, Carcao MD. et al. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease.. J Pediatr Hematol Oncol 2003; 25: 874-879.
- 14 Khair K, Baker K, Mathias M. et al. Intranasal desmopressin (OctimTM): a safe and efficacious treatment option for children with bleeding disorders.. Haemophilia 2007; 13: 548-551.
- 15 Hanebbutt FL, Rolf N, Loesel A. et al. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders.. Haemophilia 2008; 14: 524-530.
- 16 Tosetto A, Rodeghiero F, Castaman G. et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD).. J Thromb Haemost 2006; 04: 766-773.
- 17 Biss TT, Blanchette VS, Clark DS. et al. Quantitation of bleeding symptoms in children with von Willebrand disease: use of a standardized pediatric bleeding questionnaire.. J Thromb Haemost 2010; 08: 950-956.
- 18 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor defiencies.. Am J Clin Pathol 1961; 36: 212-219.
- 19 Taylor LD. The application of the biotin/avidin system to the von Willebrand factor antigen immunoassay.. Thromb Haemost 1988; 59: 251-254.
- 20 Macfarlane DE, Stibbe J, Kirby EP. et al. A method for assaying von Willebrand factor (ristocetin cofactor).. Thromb Diath Haemorrh 1975; 34: 306-311.
- 21 Woods AI, Meschengieser SS, Blanco AN. et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand’s disease.. Haematologica. 2001; 86: 420-427.
- 22 Castaman G, Lethagen S, Federici AB. et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European study MCMDM-1VWD.. Blood 2008; 111: 3531-3539.
- 23 Woods AI, Blanco AN, Chuit R. et al. Major haemorrhage related to surgery in patients with type 1 and possible type 1 von Willebrand disease.. Thromb Haemost 2008; 100: 797-802.
- 24 Robertson J, Lillicrap D, James PD. Von Willebrand disease.. Pediatr Clin North Am 2008; 55: 377-392.
- 25 Collins PW, Cumming AM, Goodeve AC. et al. Type 1 von Willebrand disease: application of emerging data to clinical practice.. Haemophilia 2008; 14: 685-696.
- 26 Smith TJ, Gill JC, Ambruso DR. et al. Hyponatremia and seizures in young children given DDAVP.. Am J Hematol 1989; 31: 199-202.
- 27 Dunn AL, Powers JR, Ribeiro MJ. et al. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: A case report and review of 40 patients.. Haemophilia 2000; 06: 11-14.
- 28 Bertholini DM, Butler CS. Severe hyponatraemia secondary to desmopressin therapy in von Willebrand’s disease.. Anaesth Intensive Care 2000; 28: 199-201.
- 29 Hyatt SA, Wang W, Kerlin BA. et al. Applying diagnostic criteria for type 1 von Willebrand disease to a pediatric population.. Pediatr Blood Cancer 2009; 52: 102-107.
- 30 Dean JA, Blanchette VS, Carcao MD. et al. von Willebrand disease in a pediatric-based population–comparison of type 1 diagnostic criteria and use of the PFA-100 and a von Willebrand factor/collagen-binding assay.. Thromb Haemost 2000; 84: 401-409.
- 31 Report summarizing data on females with von Willebrand disease.. Centers for Disease Control and Prevention.. Report on the Universal Data Collection Program. 2003; 04: 1-24.